LEVOSERT

This brand name is authorized in Austria, Croatia, Ecuador, Estonia, Ireland, Lithuania, Malta, New Zealand, Poland, Spain, UK.

Active ingredients

The drug LEVOSERT contains one active pharmaceutical ingredient (API):

1	Levonorgestrel UNII 5W7SIA7YZW - LEVONORGESTREL
	The precise mode of action of levonorgestrel as an emergency contraceptive is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest.
	Read more about Levonorgestrel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LEVOSERT Intrauterine delivery system (IUS)	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G02BA03	Plastic IUD with progestogen	G Genito urinary system and sex hormones → G02 Other gynecologicals → G02B Contraceptives for topical use → G02BA Intrauterine contraceptives
Discover more medicines within G02BA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	6299-MEE-0621, 7705-MEE-1222
EE	Ravimiamet	1500848
ES	Centro de información online de medicamentos de la AEMPS	80021
GB	Medicines & Healthcare Products Regulatory Agency	296643
HR	Agencija za lijekove i medicinske proizvode	HR-H-845986671, HR-H-896425945
LT	Valstybinė vaistų kontrolės tarnyba	1057157
MT	Medicines Authority	MA1031/00401, MA1031/00402
NZ	Medicines and Medical Devices Safety Authority	17592
PL	Rejestru Produktów Leczniczych	100301320